id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2014-E-0307-0008,FDA,FDA-2014-E-0307,Notice of Final Determination Letter from U.S. Patent and Trademark Office to CDER,Other,Letter(s),2016-12-28T05:00:00Z,2016,12,2016-12-28T05:00:00Z,,2016-12-28T14:15:11Z,,0,0,090000648243a443
FDA-2014-E-0307-0007,FDA,FDA-2014-E-0307,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2015-12-09T05:00:00Z,2015,12,2015-12-09T05:00:00Z,,2015-12-09T19:18:22Z,,0,0,0900006481d9464a
FDA-2014-E-0307-0006,FDA,FDA-2014-E-0307,"Determination of Regulatory Review Period for Purposes of Patent
Extension; STIVARGA",Notice,Determinations,2015-05-22T04:00:00Z,2015,5,2015-05-22T04:00:00Z,2015-11-19T04:59:59Z,2015-05-22T14:33:24Z,2015-12577,0,0,0900006481af150b
FDA-2014-E-0307-0005,FDA,FDA-2014-E-0307,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2015-03-31T04:00:00Z,2015,3,2015-03-31T04:00:00Z,,2015-03-31T18:40:19Z,,0,0,0900006481a7eb0a
FDA-2014-E-0307-0004,FDA,FDA-2014-E-0307,Letter from U.S. Patent and Trademark Office to FDA,Other,Letter(s),2015-02-27T05:00:00Z,2015,2,2015-02-27T05:00:00Z,,2015-02-27T14:05:46Z,,0,0,0900006481a1b5dd
FDA-2014-E-0307-0003,FDA,FDA-2014-E-0307,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2014-05-27T04:00:00Z,2014,5,2014-05-27T04:00:00Z,,2014-05-27T16:19:38Z,,0,0,0900006481715df0
FDA-2014-E-0307-0001,FDA,FDA-2014-E-0307,U.S. Patent and Trademark Office,Other,Letter(s),2014-03-14T04:00:00Z,2014,3,2014-03-14T04:00:00Z,,2014-03-14T13:22:12Z,,0,0,0900006481664c77
FDA-2014-E-0307-0002,FDA,FDA-2014-E-0307,Patent Extension from Bayer HeathCare LLC,Other,Application,2014-03-14T04:00:00Z,2014,3,2014-03-14T04:00:00Z,,2014-03-14T13:22:31Z,,0,0,0900006481664c79